Advancing technology in pharmaceutical manufacturing is widely believed to have the potential to lower the cost of manufacturing and potentially increase quality and reliability of product supply. However, there are several reasons why manufacturing in this sector has not advanced as rapidly as it has in others. In this report, Partners Richard Manning and Rich Sciacca take a high-level economic view of current issues in manufacturing of pharmaceuticals and changes in manufacturing technology. Although there are interesting and potentially valuable improvements in pharmaceutical manufacturing being explored inside many companies and academic research centers, it is an easy mistake to focus the benefits without fully recognizing the potential complications. The authors urge policy makers and thought leaders to consider both the benefits and the costs involved in adopting continuous manufacturing.
Richard Manning, PhD, and Rich Sciacca, PhD